Valuation: India Globalization Capital, Inc.

Market Cap 21.93M 19.94M 18.45M 16.61M 31.35M 2.05B 32.54M 222M 87.66M 1.11B 82.25M 80.52M 3.5B P/E 2026 *
-1.88x
P/E 2027 * -2.35x
Enterprise Value 21.93M 19.94M 18.45M 16.61M 31.35M 2.05B 32.54M 222M 87.66M 1.11B 82.25M 80.52M 3.5B EV / Sales 2026 *
22.9x
EV / Sales 2027 * 22.9x
Free-Float
90.81%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Director of Finance/CFO 55 09/05/2018
Chief Executive Officer 67 29/04/2005
Chief Operating Officer - 01/08/2019
Director TitleAgeSince
Chairman 67 29/04/2005
Director/Board Member 55 23/03/2022
Chairman 69 01/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.15%-2.81%+53.73%+71.00% 65.56B
-2.64%+0.07%+9.57%+89.87% 60.41B
-1.07%+0.55%+21.79%+87.66% 55.76B
+0.48%-0.98%+12.97%+118.46% 46.98B
-2.69%-7.62%+16.77%+25.79% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-2.50%-18.72%+140.13%+665.60% 36.09B
-0.77%-4.34%+79.27%+59.47% 32.9B
-0.83%+4.96%-36.93%+398.61% 26.96B
Average -1.06%-1.71%+34.59%+173.52% 45B
Weighted average by Cap. -0.99%-1.48%+34.18%+148.27%

Financials

2026 *2027 *
Net sales 958K 871K 806K 726K 1.37M 89.54M 1.42M 9.68M 3.83M 48.31M 3.59M 3.52M 153M 958K 871K 806K 726K 1.37M 89.54M 1.42M 9.68M 3.83M 48.31M 3.59M 3.52M 153M
Net income -10.02M -9.12M -8.44M -7.59M -14.33M -937M -14.88M -101M -40.08M -505M -37.61M -36.81M -1.6B -8.51M -7.74M -7.16M -6.44M -12.17M -795M -12.63M -85.99M -34.02M -429M -31.92M -31.25M -1.36B
Net Debt - -
Logo India Globalization Capital, Inc.
IGC Pharma, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to develop treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. It is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.
Employees
-